Preclinical studies supported this rationale, demonstrating that ficlatuzumab significantly reduced tumor-associated fibroblast-facilitated proliferation, migration, and invasion in HNSCC models by mitigating HGF/c-MET signaling and downstream MAPK phosphorylation [106]. Here, MET is linked to head and neck squamous cell carcinoma.